Overview

An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis

Status:
Completed
Trial end date:
2008-07-16
Target enrollment:
0
Participant gender:
All
Summary
Investigating the safety and tolerability of a p38 inhibitor as monotherapy in subjects who have failed at least 1 DMARD.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:

- Diagnosed with RA and has failed at least 1 DMARD therapy

Exclusion Criteria:

- Any other inflammatory arthritis and any significant history of acute or chronic
infection with immunomodulatory etiology.